Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study

被引：5
|
作者：
Ramalingam, Suresh S. [1 ]
Saka, Hideo [2 ]
Ahn, Myung-Ju [3 ]
Yu, Helena [4 ]
Horn, Leora [5 ]
Hida, Toyoaki [6 ]
Cantarini, Mireille [7 ]
Verheijen, Remy [7 ]
Wessen, Jonathan [7 ]
Oxnard, Geoffrey [8 ]
Ohe, Yuichiro [9 ]
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[2] Natl Hosp Org, Nagoya Med Ctr, Nagoya, Aichi, Japan
[3] Samsung Med Ctr, Seoul, South Korea
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[6] Aichi Canc Ctr, Nagoya, Aichi, Japan
[7] Astrazeneca, Global Med Dev, Cambridge, England
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
[9] Natl Canc Ctr, Tokyo, Japan
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-CT034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT034
引用
收藏
页数：2
相关论文
共 50 条
  • [1] TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI
    Han, J-Y.
    Sequist, L. V.
    Ahn, M-J.
    Cho, B. C.
    Yu, H.
    Kim, S-W.
    Yang, J. C-H.
    Lee, J. S.
    Su, W-C.
    Kowalski, D.
    Orlov, S.
    Cantarini, M.
    Verheijen, R. B.
    Mellemgaard, A.
    Frewer, P.
    Ou, X.
    Oxnard, G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [2] TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI
    Ahn, M.
    Han, J.
    Sequist, L.
    Cho, B. C.
    Lee, J. S.
    Kim, S.
    Su, W.
    Tsai, C.
    Yang, J. C.
    Yu, H.
    Horn, L.
    Lee, K.
    Haddad, V.
    Frigault, M.
    Ahmed, G.
    Yang, L.
    Ghiorghiu, D.
    Oxnard, G.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1768 - S1768
  • [3] The Difference in Clinical Outcomes Between Osimertinib and EGFR-TKI plus Anti-angiogenic Agent in EGFR-mutant NSCLC Patients
    Huang, Y. H.
    Hsu, K. -H.
    Tseng, J. -S.
    Chen, K. -C.
    Chang, G. -C.
    Yang, T. -Y.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S477 - S478
  • [4] Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC with Progression on Prior EGFR-TKI
    Riess, J.
    Kelly, K.
    Schalper, K.
    Shimoda, M.
    Lim, S.
    Monjazeb, A.
    Danenberg, K.
    Moore, E.
    Beckett, L.
    Mack, P.
    Maverakis, E.
    Gandara, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S528 - S528
  • [5] Safety of tepotinib plus EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC
    Nadal, E.
    Kim, T. M.
    Guarneri, V.
    Voon, P. J.
    Lim, B. K.
    Wislez, M.
    Huang, C.
    Liam, C. K.
    Mazieres, J.
    Tho, L. M.
    Hayashi, H.
    Nguyen, N.
    Chia, P. L.
    De Marinis, F.
    Brutlach, S.
    Adrian, S.
    Ellers-Lenz, B.
    Berghoff, K.
    Karachaliou, N.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2023, 34
  • [6] Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
    Remon, J.
    Steuer, C. E.
    Ramalingam, S. S.
    Felip, E.
    ANNALS OF ONCOLOGY, 2018, 29 : I20 - I27
  • [7] TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
    Sequist, Lecia V.
    Lee, Jong Seok
    Han, Ji-Youn
    Su, Wu-Chou
    Yang, James Chih-Hsin
    Yu, Helena
    Ottesen, Lone H.
    Verheijen, Remy B.
    Mellemgaard, Anders
    Wessen, Jonathan
    Oxnard, Geoffrey
    Cho, Byoung Chul
    CANCER RESEARCH, 2019, 79 (13)
  • [8] TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
    Yu, Helena
    Ahn, Myung-Ju
    Kim, Sang-We
    Cho, Byoung Chul
    Sequist, Lecia
    Orlov, Sergey
    Ottesen, Lone H.
    Verheijen, Remy B.
    Mellemgaard, Anders
    Wessen, Jonathan
    Han, Ji-Youn
    CANCER RESEARCH, 2019, 79 (13)
  • [9] Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)
    Bertino, Erin M.
    Gentzler, Ryan D.
    Clifford, Sarah
    Kolesar, Jill
    Muzikansky, Alona
    Haura, Eric B.
    Piotrowska, Zofia
    Camidge, D. Ross
    Stinchcombe, Thomas E.
    Hann, Christine
    Malhotra, Jyoti
    Villaruz, Liza C.
    Paweletz, Cloud P.
    Lau, Christie L.
    Sholl, Lynette
    Takebe, Naoko
    Moscow, Jeffrey A.
    Shapiro, Geoffrey, I
    Janne, Pasi A.
    Oxnard, Geoffrey R.
    CLINICAL CANCER RESEARCH, 2021, 27 (06) : 1604 - 1611
  • [10] A Phase Ib Study of the Combination of Afatinib and Ruxolitinib in EGFR Mutant NSCLC Progressed on EGFR-TKI: An Updated Analysis
    Park, J. S.
    Hong, M. H.
    Cho, B. C.
    Kim, H. R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1847 - S1847
12345